| Continuous evolution of SpCas9 variants compatible with non-G PAMs SM Miller, T Wang, PB Randolph, M Arbab, MW Shen, TP Huang, ... Nature biotechnology 38 (4), 471-481, 2020 | 349 | 2020 |
| Circularly permuted and PAM-modified Cas9 variants broaden the targeting scope of base editors TP Huang, KT Zhao, SM Miller, NM Gaudelli, BL Oakes, C Fellmann, ... Nature biotechnology 37 (6), 626-631, 2019 | 273 | 2019 |
| Precision genome editing using cytosine and adenine base editors in mammalian cells TP Huang, GA Newby, DR Liu Nature protocols 16 (2), 1089-1128, 2021 | 157 | 2021 |
| CRISPR-free base editors with enhanced activity and expanded targeting scope in mitochondrial and nuclear DNA BY Mok, AV Kotrys, A Raguram, TP Huang, VK Mootha, DR Liu Nature biotechnology 40 (9), 1378-1387, 2022 | 143 | 2022 |
| Evolution of an adenine base editor into a small, efficient cytosine base editor with low off-target activity ME Neugebauer, A Hsu, M Arbab, NA Krasnow, AN McElroy, S Pandey, ... Nature biotechnology 41 (5), 673-685, 2023 | 132 | 2023 |
| Efficient in vivo base editing via single adeno-associated viruses with size-optimized genomes encoding compact adenine base editors JR Davis, X Wang, IP Witte, TP Huang, JM Levy, A Raguram, S Banskota, ... Nature Biomedical Engineering 6 (11), 1272-1283, 2022 | 129 | 2022 |
| High-throughput analysis of the activities of xCas9, SpCas9-NG and SpCas9 at matched and mismatched target sequences in human cells HK Kim, S Lee, Y Kim, J Park, S Min, JW Choi, TP Huang, S Yoon, DR Liu, ... Nature biomedical engineering 4 (1), 111-124, 2020 | 120 | 2020 |
| Continuous directed evolution of proteins with improved soluble expression T Wang, AH Badran, TP Huang, DR Liu Nature chemical biology 14 (10), 972-980, 2018 | 119 | 2018 |
| Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer S Shelar, EH Shim, GJ Brinkley, A Kundu, F Carobbio, T Poston, J Tan, ... Clinical Cancer Research 24 (24), 6433-6446, 2018 | 76 | 2018 |
| High-throughput continuous evolution of compact Cas9 variants targeting single-nucleotide-pyrimidine PAMs TP Huang, ZJ Heins, SM Miller, BG Wong, PA Balivada, T Wang, ... Nature biotechnology 41 (1), 96-107, 2023 | 71 | 2023 |
| The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma E Emberley, A Pan, J Chen, R Dang, M Gross, T Huang, W Li, ... PLoS One 16 (11), e0259241, 2021 | 36 | 2021 |
| Assigning functionality to cysteines by base editing of cancer dependency genes H Li, T Ma, JR Remsberg, SJ Won, KE DeMeester, E Njomen, ... Nature chemical biology 19 (11), 1320-1330, 2023 | 30 | 2023 |
| Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases CD Vo, HL Shebert, S Zikovich, RA Dryer, TP Huang, LJ Moran, J Cho, ... Bioorganic & medicinal chemistry letters 27 (23), 5235-5244, 2017 | 26 | 2017 |
| CB-839, a selective glutaminase inhibitor, has anti-tumor activity in renal cell carcinoma and synergizes with cabozantinib and everolimus E Emberley, M Bennett, J Chen, M Gross, T Huang, W Li, A MacKinnon, ... Keystone Symposia, Tumor Metabolism: Mechanisms and Targets, Whistler Canada, 2017 | 19 | 2017 |
| Abstract B045: Arginase inhibitor CB-1158 elicits immune-mediated antitumor responses as a single agent and in combination with other immunotherapies SM Steggerda, M Bennett, J Chen, E Emberley, M Gross, T Huang, W Li, ... Cancer Immunology Research 4 (11_Supplement), B045-B045, 2016 | 15 | 2016 |
| Base editors with diversified targeting scope DR Liu, KT Zhao, TP Huang US Patent App. 17/633,573, 2022 | 13 | 2022 |
| 31st annual meeting and associated programs of the society for immunotherapy of cancer (Sitc 2016): Part two: National harbor, md, USA. 9-13 November 2016 C Ager, M Reilley, C Nicholas, T Bartkowiak, A Jaiswal, M Curran, ... Journal for ImmunoTherapy of Cancer 4, 107-221, 2016 | 13 | 2016 |
| Immuno-oncology agent CB-1158 is a potent and selective arginase inhibitor and causes an immune-mediated anti-tumor response M Works, M Bennett, J Chen, E Emberley, T Huang, J Janes, W Li, ... Cancer Research 76 (14_Supplement), 552-552, 2016 | 12 | 2016 |
| The glutaminase inhibitor CB-839 synergizes with CDK4/6 and PARP inhibitors in pre-clinical tumor models ED Emberley, M Bennett, J Chen, M Gross, T Huang, A Makkouk, ... Cancer Research 78 (13_Supplement), 3509-3509, 2018 | 11 | 2018 |
| Discovery of a Series of Potent, Selective, and Orally Bioavailable Nucleoside Inhibitors of CD73 That Demonstrates In Vivo Antitumor Activity J Li, L Chen, RJ Billedeau, TF Stanton, JTP Chiang, CC Lee, W Li, ... Journal of Medicinal Chemistry 66 (1), 345-370, 2022 | 10 | 2022 |
